Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Unknown 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Recurrence 2Leukemia 2Carcinoma, Renal Cell 2Pancreatic Neoplasms 1Ovarian Cancer Recurrent 1Neoplasms 1Neoplasm, Residual 1Melanoma 1Kidney Neoplasms 1Graft vs Host Disease 1

Interventions

Cyclophosphamide 17fludarabine 13Dexamethasone 12Cisplatin 11Rituximab 10Gemcitabine 9Paclitaxel 7Lenalidomide 7Decitabine 7Cytarabine 7Bendamustine Hydrochloride 7fludarabine phosphate 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Etoposide 6Carboplatin 6Bortezomib 6Radiotherapy 5Injections 5Azacitidine 5camrelizumab 4apatinib 4Valproic Acid 4Thalidomide 4Procarbazine 4Oxaliplatin 4Drug Therapy 4Antilymphocyte Serum 4tislelizumab 3pomalidomide 3liposomal doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Recurrence × Interferon alpha-2 × Clear all
NCT02185261 2018-06-07

Interferon α for the Therapy of Minimal Residual Disease

Peking University People's Hospital

Phase NA Unknown
81 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Leukemia, Recurrence, Neoplasm, Residual

NCT02568241 2016-09-29

IDPR-HSCT

Peking University People's Hospital

Phase 1/2 Unknown
42 enrolled
Other hematologic neoplasm

Leukemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡